Acalabrutinib

Phase 3

ASTRAZENECA PLC (AZNCF)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

AZNCFPhase 2$290.6B

Acalabrutinib Phase 2 Est. Readout

Acalabrutinib• Phase I: Relapsed or Refractory B-cell Malignancies20

Q3 2027~QConfirmed

CT.gov

00%

Jan '27

AZNCFPhase 2$290.6B

Acalabrutinib Phase 2 Est. Readout

Acalabrutinib• Phase I: Relapsed or Refractory B-cell Malignancies24

Jan 2027~Confirmed

CT.gov

00%

Sep '26

AZNCFPhase 2$290.6B

Acalabrutinib Phase 2 Est. Readout

Acalabrutinib• Phase I: Relapsed or Refractory B-cell Malignancies49

Sep 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Phase I: Relapsed or Refractory B-cell Malignancies

View Full Landscape

Drug Information

Target Indication

Phase I: Relapsed or Refractory B-cell Malignancies

Clinical Trial

NCT03932331

Last updated: 2/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AZNCF

ASTRAZENECA PLC

Biotechnology•North America•NASDAQ

Related Pipeline

Quetiapine SRPhase 3

Anxiety Disorders

MEDI3250Phase 3

Healthy Japanese Children Age 2 Years Through 6 Years

ParoxetinePhase 3

Generalized Anxiety Disorder

AZD2265Phase 3

Metastatic Castration-resistant Prostate Cancer

CapivasertibPhase 3

Triple Negative Breast Neoplasms

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts